A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder

Phase 2 Not yet recruiting 120 enrolled Chengdu Kanghong Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of KH607 in 120 participants diagnosed with moderate or severe Major Depressive Disorder.

Timeline

Start: 2025-08
Primary completion: 2025-12
Completion: 2026-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KH607	Unknown	20 mg	Oral
Subject	KH607	Unknown	30 mg	Oral

A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive Disorder

Summary

Timeline

Drugs

Indications